Gemini Study to Evaluate the Integration of Cancer Genetic Testing into a Cancer Clinical Practice at Mayo Clinic at Arizona


NCT ID: NCT04475640
Sponsor Protocol Number: GEMINI

About this study

The purpose of this study is to determine the prevalence of genetic mutations in cancer patients from various ethnic populations seeking care at Mayo Clinic Arizona cancer clinics.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients at least 18 years of age.
  • Individuals diagnosed with any solid tumor cancer including, but not limited to, gastrointestinal, breast, gynecological, genitourinary, skin, CNS/brain, head/neck, musculoskeletal or cancer of unknown primary; and presenting to Mayo Clinic for clinical management/ treatment; and patients receive genetic testing as described above.
  • Self-identified as being from various ethnic populations including Hispanic/Latino, Native American/Alaskan, African American (including of African descent),Asian and other European populations.
  • Blood collection is feasible (health, access and/or tolerability) for requested blood sample(s).
  • Individuals have agreed to participate and signed the study informed consent form.

Exclusion Criteria: 

  • Patients who have had prior germline genetic testing involving a 40+ gene panel within the last 24 months at Mayo Clinic and available for review by the research coordinator at time of consent.

More information


Publications are currently not available

Mayo Clinic Footer